PMBS News 0.0001 08/25/2014 05:30:34 Puramed Bioscience (PMB

New Post Public Reply Private Reply Replies (0) Message Board

Aug 25, 2014 at 6:30 AM

Puramed Bioscience (PMBS) 0.0001 $PMBS

PuraMed BioScience Completes the First Production of MigraPure® Gel
PR Newswire - Wed Aug 13, 11:28AM CDT
PuraMed BioScience®, Inc., (OTCPink

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that the company has completed its first batch of its patented, sublingual MigraPure® gel containing feverfew and ginger with an enhanced flavor.

PuraMed BioScience to add Cannabis-based epilepsy medication to its product line
M2 - Wed Aug 06, 5:53AM CDT
OTC medicinal company PuraMed BioScience (Other OTC

MBS) said on Tuesday that it intends to begin testing a new hemp-based epilepsy medication in the fourth quarter of 2014.

PuraMed BioScience Develops a Cannabis-based Epilepsy Medication
PR Newswire - Tue Aug 05, 1:00PM CDT
PuraMed BioScience®, Inc., (OTCPink: PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that it plans to begin testing of a new hemp-based epilepsy medication in the fourth quarter of 2014.

PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M
PR Newswire - Wed Jul 30, 12:57PM CDT
PuraMed BioScience®, Inc., (OTCPink

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that the company is rebranding the LipiGesic® M name along with the name's red and yellow logo. The former will be replaced with the trademarked name MigraPure® going forward. The new name, logo, and color palette of PuraMed's homeopathic, natural migraine pain reliever will be reintroduced into selected segments of the retail marketplace.

PuraMed BioScience forms corporate sponsor partnership with Operation Troop Aid for US military
M2 - Wed Jul 23, 7:38AM CDT
Healthcare company PuraMed BioScience (PNK

MBS) reported on Tuesday the launch of a corporate sponsor agreement with Operation Troop Aid in aid of the US military.

PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages
PR Newswire - Tue Jul 22, 7:49AM CDT
PuraMed BioScience®, Inc., (OTCBB: PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that the company is a corporate sponsor of Operation Troop Aid.

PuraMed BioScience Announces Product Donation at a Sponsorship Level to Operation Gratitude
PR Newswire - Tue Jul 08, 8:11AM CDT
PuraMed BioScience®, Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that the company is now a corporate sponsor of Operation Gratitude.

PuraMed BioScience Explores the Development of Hemp and THC-Free Cannabis Formulations to Expand Its Product Line
PRWeb - Mon Mar 24, 6:09AM CDT
PuraMed BioScience(R), Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, confirmed today that it is seriously exploring the development of cannabinoid and hemp-based formulations to expand its natural and homeopathic product line.

Energy Utilities Focus on Providing Reliable and Safe Service while Meeting Compliance Standards
PR Newswire - Wed Feb 26, 7:00AM CST
To streamline and standardize gas compliance processes and adapt to the demands of the energy service and delivery industry, Ameren Corporation has turned to the mobile workforce management market leader, ClickSoftware Technologies Ltd. (NasdaqGS: CKSW). The implementation of ClickSoftware's scheduling and mobility offering for gas compliance processes will eliminate paper inspection forms and improve data quality, improve flexibility to adapt to rapidly changing regulatory requirements, and provide management with greater visibility into compliance activities.

Merger Approval, Financial Results, Conference Call Schedule, and Stock Price Updates - Research Report on Omnicom, Global Payments, FleetCor, Interpublic, and Fiserv
PR Newswire - Wed Jan 15, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.

PuraMed BioScience Invited to Discuss LipiGesic M on Armed Forces Network
PR Newswire - Thu Aug 29, 11:03AM CDT
PuraMed BioScience®, Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that it will discuss LipiGesic M on Armed Forces Network.

PuraMed BioScience Sponsors Miles for Migraine Race with LipiGesic M
PR Newswire - Thu Aug 22, 7:00AM CDT
PuraMed BioScience®, Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that it will sponsor the 5th Miles for Migraine Race San Francisco by supplying $5,000 of LipiGesic M for the participants.

PuraMed BioScience Inc signs LipiGesic M distributor agreement with OuterBanks Outdoors
M2 - Thu Aug 15, 10:13AM CDT
Healthcare company PuraMed BioScience Inc (OTC BB

MBS) reported on Wednesday the launch of an exclusive distribution agreement to sell LipiGesic M on Amazon.com..

PuraMed BioScience Announces Distributor Agreement with OuterBanks Outdoors
PR Newswire - Wed Aug 14, 1:08PM CDT
PuraMed BioScience®, Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that it has entered into an exclusive distribution agreement with OuterBanks Outdoors to sell LipiGesic® M, its homeopathic formulation of feverfew and ginger for treatment of acute migraine, on Amazon.com.

LipiGesic M is the only recommended first-line therapy for acute migraine that has no evidence of rebound headache
PR Newswire - Mon Aug 05, 2:44PM CDT
PuraMed BioScience®, Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, confirmed today that its product, LipiGesic® M, a homeopathic formulation of feverfew and ginger that eliminates migraine pain and associated symptoms, is the only recommended first-line therapy for acute migraine in the retail market today that has shown no evidence of rebound or medication-overuse headache.

PuraMed BioScience Inc reports 42.6m outstanding shares in issue
M2 - Wed Jul 03, 4:36AM CDT
Medicinal products company PuraMed BioScience Inc (OTC BB

MBS) declared on Tuesday that its current common shares issued and outstanding totalled 42,610,297 as of 30 June 2013.

PuraMed BioScience Announces Common Shares Outstanding of 42.6 Million
PR Newswire - Tue Jul 02, 10:27AM CDT
PuraMed BioScience®, Inc., (OTCBB: PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announces update of current share structure.

PuraMed BioScience® Announces Science Behind LipiGesic® M Migraine Treatment
PR Newswire - Fri Jun 21, 10:05AM CDT
PuraMed BioScience®, Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced the science behind LipiGesic® M, its homeopathic, over-the-counter migraine medication.

PuraMed BioScience® Announces Interview on Big Biz Show Discussing LipiGesic® M
PR Newswire - Mon Jun 10, 7:00AM CDT
PuraMed BioScience®, Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced an interview conducted on Big Biz Show with PuraMed BioScience's CEO Russ Mitchell to discuss and inform listeners about PuraMed BioScience's flagship product, LipiGesic® M.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Horowitz's $150M Boost for Nevada's First Children's Hospital

Big Bucks and Bigger Hearts Boost Pediatric Care in Nevada The world isn't exactly short on folks looking to make a buck, but every so often, someone comes along and wants to make a difference instead. Enter Felicia and Ben Horowitz, handing over a staggering $150 million to Intermountain Health. This isn’t your garden-variety gift—it’s aimed at getting Nevada on...

Alaska's Insurance Maze: Coverage Over Cheap Policies

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Ares Commercial Real Estate Gears Up for Q3 Earnings

Earnings Season Descends on Ares Commercial Real Estate The hush before the storm is here, comrades. Ares Commercial Real Estate Corporation (NYSE: ACRE) has set the ticker tape rolling as they prepare to unveil the fiscal secrets of their third quarter on November 6, 2026. If you’ve got skin in the game or just an ear for market music, mark your calendars because the...

HumanView Relaunch: LEAP Group Decodes Customer Signals

Understanding Customer Signals Like Never Before Well, here's one for the ol' playbook. The LEAP Group just dusted off their tool, HumanView, like an old car getting a fresh coat of paint and an engine overhaul. It's been rebuilt from the ground up, promising to turn those random blips of online chatter into actionable business insights. Not the same old dashboard mumbo...

Denarius Metals Unveils Technical Insight for Toral Project

Denarius Metals Shares Tech Report on Toral Project It's a curious moment in the mining world when Denarius Metals decides to drop their latest gem—a technical report on the Toral Project. We're talking about a full-bodied document rooted in the stringent National Instrument 43-101 standards. This isn't some half-baked release; it's a robust assertion of where they...

Ensign Lawsuit Brews: Investor Stakes High by Dec. 7

Ensign's Alleged Missteps Uncovered Man, grabbing headlines in the finance world often feels like catching a whirlwind, and yet, here we are with Ensign Group's latest debacle. This isn't some run-of-the-mill story we're sifting through. It's a class action lawsuit with teeth, aiming to rope in investors who played ball during a hefty stretch running from February 10,...

Gildan Faces Lawsuit: Allegations of Deceptive Practices Shake Investors

Gildan's Troubles Unveiled The financial jungle can be a pretty treacherous place, and Gildan Activewear Inc. (NYSE: GIL) just found out how fickle the market can be. An 18.7% nosedive in Gildan's stock price after a securities fraud class action came knocking—if that isn't enough to stir up a hornet’s nest among investors, I don’t know what is. The Catalyst:...

Amy Johnson Steps Up as GDIT President Amid Shifts

A New Chapter for GDIT with a Veteran Leader Big shoes to fill? Nah, more like Amy Johnson was made for these shoes. Stepping up as president of General Dynamics Information Technology (GDIT) on November 3, she’s got 27 years of experience under her belt, all from General Dynamics' own backyard. This ain't her first rodeo. From tightrope-walking the perils of defense...

Bio-Thera's New Data: A Game Changer for NSCLC?

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Howard Hughes Joins S&P SmallCap 600, Arcosa Out

Shakeup in the S&P SmallCap 600 It’s one of those days where something shifts in the market landscape—Howard Hughes Holdings Inc. (NYSE: HHH) is swaggering into the S&P SmallCap 600. Kicking off on October 28, it's got quite the entrance lined up. On the other end, Arcosa Inc. (NYSE: ACA) is making a hasty exit after getting scooped up by CRH plc (NYSE: CRH). For...